A randomised controlled trial of high dose vitamin D in recent-onset type 2 diabetes
Shirley Elkassaby, Leonard C Harrison, Namita Mazzitelli, John M Wentworth, Peter G Colman, Timothy Spelman, Spiros Fourlanos
Diabetes Research and Clinical Practice | ELSEVIER IRELAND LTD | Published : 2014
AIMS: Vitamin D insufficiency has been associated with impaired pancreatic beta-cell function. We aimed to determine if high dose oral vitamin D3 (D) improves beta-cell function and glycaemia in type 2 diabetes. METHODS: Fifty adults with type 2 diabetes diagnosed less than 12 months, with normal baseline serum 25-OH D (25D), were randomised to 6000 IU D (n=26) or placebo (n=24) daily for 6 months. Beta-cell function was measured by glucagon-stimulated serum C-peptide (delta C-peptide [DCP], nmol/l). Secondary outcome measures were fasting plasma glucose (FPG), post-prandial blood glucose (PPG), HbA1c and insulin resistance (HOMA-IR). RESULTS: In the D group, median serum 25D (nmol/l) increa..View full abstract
This work was funded by grants from The Munro Foundation, Melbourne, and Diabetes Australia Research Trust, and supported by Victorian State Government Operational Infrastructure Support and Australian Government NHMRC IRIIS. SE was a Postgraduate Scholar of the National Health and Medical Research Council of Australia (NHMRC) and received a Basser Family Scholarship from the Royal Australasian College of Physicians. LCH is a Senior Principal Research Fellow of the NHMRC.